![]() |
½ÃÀ庸°í¼
»óǰÄÚµå
1629636
°æÄ«Å×ÅÍ ´ëµ¿¸ÆÆÇ ġȯ¼ú(TAVR) ½ÃÀå : ½Ã¼ú À¯Çüº°, µð¹ÙÀ̽º À¯Çüº°, ÃÖÁ¾»ç¿ëÀÚº°, Áö¿ªº°Transcatheter Aortic Valve Replacement Market, By Procedure Type, By Device Type, By End User, By Geography |
°æÄ«Å×ÅÍ µ¿¸ÆÆÇ ġȯ¼ú(TAVR) ½ÃÀå ¼¼°è ½ÃÀåÀº 2024³â¿¡ 67¾ï 1,000¸¸ ´Þ·¯·Î ÃßÁ¤µË´Ï´Ù. 2031³â¿¡´Â 108¾ï ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹»óµÇ¸ç, 2024³âºÎÅÍ 2031³â±îÁö 7%ÀÇ ¿¬Æò±Õ º¹ÇÕ ¼ºÀå·ü(CAGR)À» ³ªÅ¸³¾ Àü¸ÁÀÔ´Ï´Ù.
º¸°í ¹üÀ§ | º¸°í¼ »ó¼¼ ³»¿ë | ||
---|---|---|---|
±âÁØ ¿¬µµ | 2023³â | 2024³â ½ÃÀå ±Ô¸ð | 67¾ï 1,000¸¸ ´Þ·¯ |
½ÇÀû µ¥ÀÌÅÍ | 2019-2023³â | ¿¹Ãø ±â°£ | 2024-2031³â |
¿¹Ãø ±â°£(2024-2031³â)ÀÇ ¿¬Æò±Õ º¹ÇÕ ¼ºÀå·ü(CAGR) : | 7.00% | 2031³â °¡Ä¡ ¿¹Ãø | 108¾ï ´Þ·¯ |
°æÇÇÀû ´ëµ¿¸ÆÆÇ¸· ġȯ¼ú(TAVR) ¼¼°è ½ÃÀåÀº ³ëÀÎ Àα¸ Áõ°¡¿Í Àü ¼¼°è ´ëµ¿¸ÆÆÇ¸· ÇùÂøÁõ À¯º´·ü Áõ°¡¿¡ ÈûÀÔ¾î Áö³ 10³â°£ ºü¸£°Ô ¼ºÀåÇϰí ÀÖÀ¸¸ç, TAVR ½Ã¼úÀº °³½É¼úÀÇ À§ÇèÀÌ ³ôÀº ÁßÁõ ´ëµ¿¸ÆÆÇ¸· ÇùÂøÁõ ȯÀÚ¿¡°Ô ÃÖ¼Ò Ä§½ÀÀû Ä¡·á ¿É¼ÇÀ» Á¦°øÇÕ´Ï´Ù. ÀÌ ½Ã¼úÀº Á¢À» ¼ö ÀÖ´Â Àΰø ½ÉÀå ÆÇ¸·À» Ä«Å×Å͸¦ ÅëÇØ ü³»·Î »ðÀÔÇÏ¿© º´º¯ÀÌ ÀÖ´Â ¿ø·¡ÀÇ ´ëµ¿¸Æ ÆÇ¸· ¾ÈÂÊ¿¡ ¼³Ä¡ÇÕ´Ï´Ù. TAVRÀÇ ¾ÈÀü¼º, À¯È¿¼º, ¼ö¸íÀÌ ´õ ¸¹Àº ÀÓ»óÀû Áõ°Å¸¦ ÅëÇØ ÀÔÁõµÊ¿¡ µû¶ó ȯÀÚ ÀÚ°Ý ±âÁØÀÌ È®´ëµÇ°í, ºÏ¹Ì µî ÁÖ¿ä Áö¿ª¿¡¼ TAVRÀÇ ±¤¹üÀ§ÇÑ ½ÃÀå µµÀÔÀÌ ÃßÁøµÇ°í ÀÖ½À´Ï´Ù. ƯÈ÷ ¹ëºê Àü´Þ ½Ã½ºÅÛ¿¡ ´ëÇÑ ±¤¹üÀ§ÇÑ ±â¼ú ¹ßÀü°ú ½ÅÁ¦Ç° ½ÂÀεµ TAVRÀÇ ¼¼°è º¸±ÞÀ» ÃËÁøÇϰí ÀÖ½À´Ï´Ù.
°æÄ«Å×ÅÍ µ¿¸ÆÆÇ ġȯ¼ú(TAVR) ½ÃÀå ¼¼°è ½ÃÀåÀº ÁÖ·Î ´ëµ¿¸ÆÆÇ¸· ÇùÂøÁõ¿¡ Ãë¾àÇÑ ³ëÀÎ Àα¸ÀÇ ±Þ°ÝÇÑ Áõ°¡¿¡ ÀÇÇØ ÁÖµµµÇ°í ÀÖ½À´Ï´Ù. ¼¼°è Æò±Õ ¼ö¸í Áõ°¡¿Í Àα¸ °í·ÉÈ·Î ÀÎÇØ ½ÉÀå ÆÇ¸· ġȯ¼úÀÌ ÇÊ¿äÇÑ È¯ÀÚ ¼ö°¡ Å©°Ô Áõ°¡Çϰí ÀÖÀ¸¸ç, 2024³â 10¿ù WHOÀÇ Ã߻꿡 µû¸£¸é 2015³â¿¡¼ 2050³â »çÀÌ¿¡ 60¼¼ ÀÌ»óÀÇ ¼¼°è Àα¸°¡ 12%¿¡¼ 22%·Î µÎ ¹è·Î Áõ°¡ÇÒ °ÍÀ¸·Î ¿¹»óµÇ°í ÀÖ½À´Ï´Ù. ½ÉÇ÷°ü ÁúȯÀÇ ºÎ´ã Áõ°¡¿Í ÃÖ¼Ò Ä§½À ¼ö¼ú¿¡ ´ëÇÑ ÀνÄÀÌ ³ô¾ÆÁö¸é¼ °æÇÇÀû ´ëµ¿¸ÆÆÇ¸· ġȯ¼úÀÇ Ã¤ÅÃÀÌ ´õ¿í °¡¼Óȵǰí ÀÖ½À´Ï´Ù. °æÄ«Å×ÅÍ Á¢±Ù¹ýÀº ȸº¹ ½Ã°£ ´ÜÃà, ÀÔ¿ø ±â°£ ´ÜÃà, ÇÕº´Áõ À§Çè °¨¼Ò, ƯÈ÷ °íÀ§Ç豺 ȯÀÚ¿¡¼ °³½É¼úº¸´Ù ¼±È£µÇ°í ÀÖ½À´Ï´Ù. ±×·¯³ª Àα¸ÀÇ ´ë´Ù¼ö°¡ °í±Þ ½ÉÀå ÀÇ·á ¼ºñ½º¸¦ ¹ÞÁö ¸øÇÏ´Â ½ÅÈï±¹¿¡¼´Â °æÇÇÀû ´ëµ¿¸ÆÆÇ¸· ġȯ¼ú ½ÃÀå °³¹ß ÀáÀç·ÂÀÌ ¾ÆÁ÷ ¹Ì°³¹ßµÈ »óÅÂÀÔ´Ï´Ù.
¼¼°èÀÇ °æÄ«Å×ÅÍ µ¿¸ÆÆÇ ġȯ¼ú(TAVR) ½ÃÀå(Transcatheter Aortic Valve Replacement) ½ÃÀå¿¡ ´ëÇØ Á¶»ç ºÐ¼®ÇßÀ¸¸ç, 2023³âÀ» ±âÁØ ¿¬µµ, 2024-2031³â ¿¹Ãø ±â°£(2024-2031³â) ½ÃÀå ±Ô¸ð(10¾ï ´Þ·¯)¿Í ¿¬Æò±Õ ¼ºÀå·ü(CAGR)À» »ó¼¼ÇÏ°Ô Á¶»çÇÏ¿© ÀüÇØµå¸³´Ï´Ù.
¶ÇÇÑ ´Ù¾çÇÑ ºÎ¹®¿¡ °ÉÄ£ ÀáÀçÀû ¼öÀÍ Ã¢Ãâ ±âȸ¸¦ ¹àÈ÷°í, ÀÌ ½ÃÀåÀÇ ¸Å·ÂÀûÀÎ ÅõÀÚ Á¦¾È ¸ÅÆ®¸¯½º¸¦ ¼³¸íÇÕ´Ï´Ù.
¶ÇÇÑ ½ÃÀå ¼ºÀå ÃËÁø¿äÀÎ, ¾ïÁ¦¿äÀÎ, ±âȸ, ½ÅÁ¦Ç° Ãâ½Ã ¹× ½ÂÀÎ, ½ÃÀå µ¿Çâ, Áö¿ªº° Àü¸Á, ÁÖ¿ä ±â¾÷ÀÇ °æÀï Àü·« µî¿¡ ´ëÇÑ ÁÖ¿ä °íÂûÀ» Á¦°øÇÕ´Ï´Ù.
°æÇÇÀû ´ëµ¿¸Æ ÆÇ¸· ġȯ¼ú ¼¼°è ½ÃÀå¿¡¼ ÁÖ¿ä ±â¾÷ ÇÁ·ÎÆÄÀÏÀ» ±â¾÷ ÇÏÀ̶óÀÌÆ®, Á¦Ç° Æ÷Æ®Æú¸®¿À, ÁÖ¿ä ÇÏÀ̶óÀÌÆ®, ½ÇÀû, Àü·« µîÀÇ ¸Å°³ º¯¼ö¸¦ ±â¹ÝÀ¸·Î ÀÛ¼ºµÇ¾ú½À´Ï´Ù.
ÀÌ º¸°í¼¿¡¼ ´Ù·ç´Â ÁÖ¿ä ±â¾÷À¸·Î´Â Edwards Lifesciences Corp, JenaValve Technology GmbH, Cardiovascular Systems, Inc., Symetis SA, Lepu Medical Technology Co. AtriCure, Inc., Vascular Solutions, Inc., Biotronik SE &Co.KG. µîÀÌ ÀÖ½À´Ï´Ù.
ÀÌ º¸°í¼ÀÇ ÅëÂû·ÂÀ» ÅëÇØ ¸¶ÄÉÆÃ ´ã´çÀÚ¿Í ±â¾÷ °æ¿µÁøÀº ÇâÈÄ Á¦Ç° Ãâ½Ã, À¯ÇüÈ, ½ÃÀå È®´ë ¹× ¸¶ÄÉÆÃ Àü·«¿¡ ´ëÇÑ Á¤º¸¿¡ ÀÔ°¢ÇÑ ÀÇ»ç°áÁ¤À» ³»¸± ¼ö ÀÖ½À´Ï´Ù.
°æÄ«Å×ÅÍ µ¿¸ÆÆÇ ġȯ¼ú(TAVR) ½ÃÀå ¼¼°è ½ÃÀå º¸°í¼´Â ÅõÀÚÀÚ, °ø±Þ¾÷ü, Á¦Ç° Á¦Á¶¾÷ü, À¯Åë¾÷ü, ½Å±Ô ½ÃÀå ÁøÃâ±â¾÷, À繫 ºÐ¼®°¡ µî ÀÌ »ê¾÷ÀÇ ´Ù¾çÇÑ ÀÌÇØ°ü°èÀÚ¸¦ ´ë»óÀ¸·Î ÇÕ´Ï´Ù.
ÀÌÇØ°ü°èÀÚµéÀº ¼¼°è °æÇÇÀû ´ëµ¿¸Æ ÆÇ¸· ġȯ¼ú ½ÃÀå ºÐ¼®¿¡ »ç¿ëµÇ´Â ´Ù¾çÇÑ Àü·« ¸ÅÆ®¸¯½º¸¦ ÅëÇØ ÀÇ»ç°áÁ¤À» ½±°Ô ³»¸± ¼ö ÀÖ½À´Ï´Ù.
The global transcatheter aortic valve replacement market is estimated to be valued at USD 6.71 Bn in 2024 and is expected to reach USD 10.80 Bn by 2031, exhibiting a compound annual growth rate (CAGR) of 7% from 2024 to 2031.
Report Coverage | Report Details | ||
---|---|---|---|
Base Year: | 2023 | Market Size in 2024: | US$ 6.71 Bn |
Historical Data for: | 2019 To 2023 | Forecast Period: | 2024 To 2031 |
Forecast Period 2024 to 2031 CAGR: | 7.00% | 2031 Value Projection: | US$ 10.80 Bn |
The global transcatheter aortic valve replacement market has been growing rapidly over the past decade backed by the rising geriatric population and increasing prevalence of aortic stenosis globally. TAVR procedures offer a minimally invasive treatment option for severe aortic stenosis patients who are at high risk for open-heart surgeries. The technique involves threading a collapsible prosthetic heart valve through a catheter into the body and placing it inside the diseased native aortic valve. This method reduces risks associated with open-heart surgeries such as severe bleeding, infections, and long hospital recovery times. As more clinical evidence demonstrates the safety, efficacy, and longevity of TAVR patient eligibility criteria have expanded, driving wider market adoption in key regions such as North America. Widespread technological advancements especially around valve delivery systems and new product approvals too have boosted the uptake of TAVR globally.
The global transcatheter aortic valve replacement market is primarily driven by the rapidly growing geriatric population base that is more susceptible to aortic stenosis. Rising life expectancy and aging demographics worldwide have significantly upscaled the patient pool requiring heart valve replacements. In October 2024, as per the WHO estimates, the global population aged 60 years and over is projected to double from 12% to 22% between 2015 and 2050. Growing burden of cardiovascular diseases and increasing awareness about minimally invasive procedures have further propelled the adoption of transcatheter aortic valve replacement. Transcatheter approaches are preferred over open-heart surgeries since they offer shortened recovery times, reduced hospital stays, and lower complication risks, especially for high-risk patients. However, the market potential of transcatheter aortic valve replacement is still untapped in developing nations where a majority population lacks access to advanced cardiac care.
This report provides in-depth analysis of the global transcatheter aortic valve replacement market, and provides market size (USD Bn) and compound annual growth rate (CAGR%) for the forecast period (2024-2031), considering 2023 as the base year
It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by key players
It profiles key players in the global transcatheter aortic valve replacement market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
Key companies covered as a part of this study include Edwards Lifesciences Corp., Medtronic Plc., Abbott Laboratories., Boston Scientific Corp., MicroPort Scientific Corp., JenaValve Technology GmbH., Cardiovascular Systems, Inc., Symetis SA., Lepu Medical Technology Co., Ltd., Terumo Corporation., St. Jude Medical (now part of Abbott)., AtriCure, Inc., Vascular Solutions, Inc., Biotronik SE & Co. KG., and Cook Medical
Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
The global transcatheter aortic valve replacement market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global transcatheter aortic valve replacement market